In an effort led by Thermo Fisher Scientific's Biomarkers Research Initiatives in Mass Spectrometry Center, several leading proteomics teams have completed a study examining the inter-lab reproducibility of selected-reaction monitoring assays applied to clinical samples treated with upfront protein enrichment techniques.
BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.